Pentoxifyllin in vitro és klinikai hatása a természetes ölösejt aktivitásra.

Translated title of the contribution: In vitro and clinical effect of pentoxifylline on natural killer cell activity

Z. Nagy, R. Sipka, I. Ocsovszki, A. Balogh, Y. Mándi

Research output: Contribution to journalArticle

Abstract

Pentoxifylline used in the treatment of vascular diseases has also some immunological effects. Among of these effects the influence of pentoxifylline on the natural killer cell activity was studied. In in vitro experiments the human natural killer cell cytotoxicity was examined in the presence of pentoxifylline. In our clinical trial we investigated the topic whether this drug has an immunomodulatory effect while administering it for different periods. The natural cytotoxicity of macroangiopathic patients treated with pentoxifylline was compared with the values of healthy controls and patients suffering from vascular disease and obtaining no pentoxifylline therapy. Sixty two macroangiopathic patients and twenty healthy controls were investigated altogether. In the in vitro natural killer cell reaction we found that the pentoxifylline was able to suppress the cytotoxicity at any time of the reaction. The influence of pentoxifylline on natural killer cell activity was neither due to the expression of intercellular adhesion molecule-1, nor to the alteration of membrane fluidity. However, this drug significantly (p <0.05) decreases the apoptosis of target cells. The natural killer cell activity of patients with chronic pentoxifylline therapy lasting for more than a year was proved to be significantly (p <0.005) lower. The presence of vascular disease does not influence the natural killer activity by itself. Concluding our results we can state that the suppressing effect of pentoxifylline on natural killer cell activity needs to be taken into consideration in case of clinical diseases where this drug is administered chronically.

Original languageHungarian
Pages (from-to)2441-2445
Number of pages5
JournalOrvosi Hetilap
Volume139
Issue number41
Publication statusPublished - Oct 11 1998

Fingerprint

Pentoxifylline
Natural Killer Cells
Vascular Diseases
Pharmaceutical Preparations
In Vitro Techniques
Membrane Fluidity
Intercellular Adhesion Molecule-1
Therapeutics
Clinical Trials
Apoptosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pentoxifyllin in vitro és klinikai hatása a természetes ölösejt aktivitásra. / Nagy, Z.; Sipka, R.; Ocsovszki, I.; Balogh, A.; Mándi, Y.

In: Orvosi Hetilap, Vol. 139, No. 41, 11.10.1998, p. 2441-2445.

Research output: Contribution to journalArticle

@article{229a7f200b5e4b5baa7eb0f5048298e8,
title = "Pentoxifyllin in vitro {\'e}s klinikai hat{\'a}sa a term{\'e}szetes {\"o}l{\"o}sejt aktivit{\'a}sra.",
abstract = "Pentoxifylline used in the treatment of vascular diseases has also some immunological effects. Among of these effects the influence of pentoxifylline on the natural killer cell activity was studied. In in vitro experiments the human natural killer cell cytotoxicity was examined in the presence of pentoxifylline. In our clinical trial we investigated the topic whether this drug has an immunomodulatory effect while administering it for different periods. The natural cytotoxicity of macroangiopathic patients treated with pentoxifylline was compared with the values of healthy controls and patients suffering from vascular disease and obtaining no pentoxifylline therapy. Sixty two macroangiopathic patients and twenty healthy controls were investigated altogether. In the in vitro natural killer cell reaction we found that the pentoxifylline was able to suppress the cytotoxicity at any time of the reaction. The influence of pentoxifylline on natural killer cell activity was neither due to the expression of intercellular adhesion molecule-1, nor to the alteration of membrane fluidity. However, this drug significantly (p <0.05) decreases the apoptosis of target cells. The natural killer cell activity of patients with chronic pentoxifylline therapy lasting for more than a year was proved to be significantly (p <0.005) lower. The presence of vascular disease does not influence the natural killer activity by itself. Concluding our results we can state that the suppressing effect of pentoxifylline on natural killer cell activity needs to be taken into consideration in case of clinical diseases where this drug is administered chronically.",
author = "Z. Nagy and R. Sipka and I. Ocsovszki and A. Balogh and Y. M{\'a}ndi",
year = "1998",
month = "10",
day = "11",
language = "Hungarian",
volume = "139",
pages = "2441--2445",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "41",

}

TY - JOUR

T1 - Pentoxifyllin in vitro és klinikai hatása a természetes ölösejt aktivitásra.

AU - Nagy, Z.

AU - Sipka, R.

AU - Ocsovszki, I.

AU - Balogh, A.

AU - Mándi, Y.

PY - 1998/10/11

Y1 - 1998/10/11

N2 - Pentoxifylline used in the treatment of vascular diseases has also some immunological effects. Among of these effects the influence of pentoxifylline on the natural killer cell activity was studied. In in vitro experiments the human natural killer cell cytotoxicity was examined in the presence of pentoxifylline. In our clinical trial we investigated the topic whether this drug has an immunomodulatory effect while administering it for different periods. The natural cytotoxicity of macroangiopathic patients treated with pentoxifylline was compared with the values of healthy controls and patients suffering from vascular disease and obtaining no pentoxifylline therapy. Sixty two macroangiopathic patients and twenty healthy controls were investigated altogether. In the in vitro natural killer cell reaction we found that the pentoxifylline was able to suppress the cytotoxicity at any time of the reaction. The influence of pentoxifylline on natural killer cell activity was neither due to the expression of intercellular adhesion molecule-1, nor to the alteration of membrane fluidity. However, this drug significantly (p <0.05) decreases the apoptosis of target cells. The natural killer cell activity of patients with chronic pentoxifylline therapy lasting for more than a year was proved to be significantly (p <0.005) lower. The presence of vascular disease does not influence the natural killer activity by itself. Concluding our results we can state that the suppressing effect of pentoxifylline on natural killer cell activity needs to be taken into consideration in case of clinical diseases where this drug is administered chronically.

AB - Pentoxifylline used in the treatment of vascular diseases has also some immunological effects. Among of these effects the influence of pentoxifylline on the natural killer cell activity was studied. In in vitro experiments the human natural killer cell cytotoxicity was examined in the presence of pentoxifylline. In our clinical trial we investigated the topic whether this drug has an immunomodulatory effect while administering it for different periods. The natural cytotoxicity of macroangiopathic patients treated with pentoxifylline was compared with the values of healthy controls and patients suffering from vascular disease and obtaining no pentoxifylline therapy. Sixty two macroangiopathic patients and twenty healthy controls were investigated altogether. In the in vitro natural killer cell reaction we found that the pentoxifylline was able to suppress the cytotoxicity at any time of the reaction. The influence of pentoxifylline on natural killer cell activity was neither due to the expression of intercellular adhesion molecule-1, nor to the alteration of membrane fluidity. However, this drug significantly (p <0.05) decreases the apoptosis of target cells. The natural killer cell activity of patients with chronic pentoxifylline therapy lasting for more than a year was proved to be significantly (p <0.005) lower. The presence of vascular disease does not influence the natural killer activity by itself. Concluding our results we can state that the suppressing effect of pentoxifylline on natural killer cell activity needs to be taken into consideration in case of clinical diseases where this drug is administered chronically.

UR - http://www.scopus.com/inward/record.url?scp=0032508756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032508756&partnerID=8YFLogxK

M3 - Article

C2 - 9805458

AN - SCOPUS:0032508756

VL - 139

SP - 2441

EP - 2445

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 41

ER -